HOUSE OPERATIONS/INTERGOVERNMENTAL SUBCMTE. AIDE ZELLER MOVES TO FDA
Executive Summary
HOUSE OPERATIONS/INTERGOVERNMENTAL SUBCMTE. AIDE ZELLER MOVES TO FDA April 19 to become special assistant to Deputy Commissioner for Policy Michael Taylor. Mitchell Zeller has worked as an aide to the House Government Operations/Intergovernmental Relations Subcommittee since late 1988 and is the last professional staff member who served under the late Chairman Rep. Weiss (D-N.Y.), who died last September and has been succeeded by Rep. Towns (D-N.Y.). The subcommittee was reorganized on Feb. 18 but will continue to oversee FDA operations. The new chairman is said to be interested in health care reform and in ensuring that user fee revenues are used to expedite the agency's drug approval process. However, in the wake of Weiss' death ("The Pink Sheet" Sept. 21, 1992, T&G-8) and the departure of his staff, the subcommittee is not likely to continue the kind of detailed scrutiny of FDA's scientific decisionmaking it conducted in the past. FDA issues Zeller worked on include FDA policy concessions to the Bush Administration's Council on Competitiveness, the label claims approved by FDA for the anti-arrhythmic drugs Tambocor and Enkaid, contamination problems with the nutritional supplement L- tryptophan, health claims for foods, and animal drug residues.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth